Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | BELLWAVE-001: nemtabrutinib in patients with R/R CLL/SLL

Jennifer Woyach • 8 Jun 2022
EHA 2022
Chronic Lymphocytic Leukemia Leukemia Small Lymphocytic Lymphoma Nemtabrutinib

Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, shares the results of a Phase I study of nemtabrutinib, a non-covalent BTK inhibitor in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; NCT03162536). Whilst the initial results appear promising, with high response rates, a longer follow-up is required to evaluate the durability of response to this drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Jennifer Woyach

1:04
6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLL
Jennifer Woyach • 8 Dec 2023
1:18
Pirtobrutinib in patients with CLL/SLL previously exposed to covalent BTKi: insights from BRUIN
Jennifer Woyach • 8 Dec 2023
2:57
LP-168: a novel next-generation BTK inhibitor with dual activity in CLL
Jennifer Woyach • 8 Dec 2023
0:49
BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL
Jennifer Woyach • 7 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals